A study testing whether a GLP-1 medicine from Shanghai World Leader Pharmaceutical Co., semaglutide, can help with weight.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Male or female participants aged >=18 years and <= 65 years.
• Body Mass Index (BMI) at screening between 27.0 and 35.0 kg/m² (inclusive).
• Weight change of no more than ±5% during the 3 months prior to screening with diet and exercise alone (self-reported).
• Participants (including males) must have no plans for conception during the study and within 3 months after the last administration, and must agree to use effective contraceptive methods and refrain from donating sperm or eggs during this period.
• Negative anti-HIV antibody test result at screening.

Key exclusion criteria

• Diagnosis of type 1, type 2, or other forms of diabetes mellitus.
• Prior diagnosis of obesity caused by monogenic mutations or other medical conditions, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism-related obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism.
• Prior history of bariatric surgery (excluding participants who had liposuction, abdominoplasty, intragastric balloon removal, or duodenal-jejunal bypass sleeve removal >1 year prior), or plan to undergo bariatric surgery or use weight-loss devices during the study.
• Use of any of the following treatments within 3 months prior to screening:
• Approved or unapproved anti-obesity medications (e.g., liraglutide, semaglutide, benaglutide, tirzepatide, orlistat, phentermine/topiramate, naltrexone/bupropion), or herbal supplements, health products, meal replacements, or weight-loss capsules that may affect body weight;